Show simple item record

dc.contributor.authorRodriguez‐Aponte, Sergio A
dc.contributor.authorNaranjo, Christopher A
dc.contributor.authorJohnston, Ryan S
dc.contributor.authorDalvie, Neil C
dc.contributor.authorCrowell, Laura E
dc.contributor.authorBajoria, Sakshi
dc.contributor.authorKumru, Ozan S
dc.contributor.authorJoshi, Sangeeta B
dc.contributor.authorVolkin, David B
dc.contributor.authorLove, J Christopher
dc.date.accessioned2025-11-03T21:52:01Z
dc.date.available2025-11-03T21:52:01Z
dc.date.issued2023-03-17
dc.identifier.urihttps://hdl.handle.net/1721.1/163511
dc.description.abstractAnalytical characterization of proteins is a critical task for developing therapeutics and subunit vaccine candidates. Assessing candidates with a battery of biophysical assays can inform the selection of one that exhibits properties consistent with a given target product profile (TPP). Such assessments, however, require several milligrams of purified protein, and ideal assessments of the physicochemical attributes of the proteins should not include unnatural modifications like peptide tags for purification. Here, we describe a fast two‐stage minimal purification process for recombinant proteins secreted by the yeast host <jats:italic>Komagataella phaffii</jats:italic> from a 20 mL culture supernatant. This method comprises a buffer exchange and filtration with a Q‐membrane filter and we demonstrate sufficient removal of key supernatant impurities including host‐cell proteins (HCPs) and DNA with yields of 1–2 mg and &gt;60% purity. This degree of purity enables characterizing the resulting proteins using affinity binding, mass spectrometry, and differential scanning calorimetry. We first evaluated this method to purify an engineered SARS‐CoV‐2 subunit protein antigen and compared the purified protein to a conventional two‐step chromatographic process. We then applied this method to compare several SARS‐CoV‐2 RBD sequences. Finally, we show this simple process can be applied to a range of other proteins, including a single‐domain antibody, a rotavirus protein subunit, and a human growth hormone. This simple and fast developability methodology obviates the need for genetic tagging or full chromatographic development when assessing and comparing early‐stage protein therapeutics and vaccine candidates produced in <jats:italic>K. phaffii</jats:italic>.</jats:p>en_US
dc.language.isoen
dc.publisherWileyen_US
dc.relation.isversionof10.1002/bit.28385en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceWileyen_US
dc.titleMinimal purification method enables developability assessment of recombinant proteinsen_US
dc.typeArticleen_US
dc.identifier.citationAnalytical characterization of proteins is a critical task for developingtherapeutics and subunit vaccine candidates. Assessing candidates with abattery of biophysical assays can inform the selection of one that exhibitsproperties consistent with a given target product profile (TPP). Such assess-ments, however, require several milligrams of purified protein, and idealassessments of the physicochemical attributes of the proteins should notinclude unnatural modifications like peptide tags for purification. Here, wedescribe a fast two‐stage minimal purification process for recombinant proteinssecreted by the yeast host Komagataella phaffii from a 20 mL culturesupernatant. This method comprises a buffer exchange and filtration with aQ‐membrane filter and we demonstrate sufficient removal of key supernatantimpurities including host‐cell proteins (HCPs) and DNA with yields of 1–2 mgand >60% purity. This degree of purity enables characterizing the resultingproteins using affinity binding, mass spectrometry, and differential scanningcalorimetry. We first evaluated this method to purify an engineered SARS‐CoV‐2subunit protein antigen and compared the purified protein to a conventionaltwo‐step chromatographic process. We then applied this method to compareseveral SARS‐CoV‐2 RBD sequences. Finally, we show this simple process can beapplied to a range of other proteins, including a single‐domain antibody, arotavirus protein subunit, and a human growth hormone. This simple and fastdevelopability methodology obviates the need for genetic tagging or fullchromatographic development when assessing and comparing early‐stageprotein therapeutics and vaccine candidates produced in K. phaffii.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentRagon Institute of MGH, MIT and Harvarden_US
dc.relation.journalBiotechnology and Bioengineeringen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2025-11-03T21:36:21Z
dspace.orderedauthorsRodriguez‐Aponte, SA; Naranjo, CA; Johnston, RS; Dalvie, NC; Crowell, LE; Bajoria, S; Kumru, OS; Joshi, SB; Volkin, DB; Love, JCen_US
dspace.date.submission2025-11-03T21:36:22Z
mit.journal.volume121en_US
mit.journal.issue8en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record